Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.

Chemotherapy-induced hair loss may be linked to immune system changes, and certain treatments could help but need careful use.

Vaccines and targeting TrxR variants can help prevent cancer and reduce metastasis.

Long-term use of calcineurin inhibitors in transplant patients can cause hormone issues that can be managed with proper care.

Intralesional cidofovir may be a viable alternative treatment for SCC.

Topical cyclosporin A doesn't work for alopecia totalis because it doesn't penetrate the skin well.

Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.

Oral ciclosporin A and topical treatments both reduce hair loss and scaling in dogs with sebaceous adenitis, but using both together is most effective.

Oral valganciclovir improved a patient's skin condition caused by immunosuppression.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

Cetuximab often causes skin rashes, and managing these is important for cancer treatment.

Cyclosporine improved skin condition in dogs with sebaceous adenitis.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

Oral cyclosporine A and prednisolone effectively improved alopecia universalis without side effects.

Mycophenolate mofetil is safer and more effective than cyclophosphamide for treating lupus nephritis.

PI3Kδ inhibition may effectively treat cutaneous chronic graft-versus-host disease.

Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.

Cyclosporine A treatment caused rare hair repigmentation in a 65-year-old man.

Topical cyclosporin promotes hair growth.

Nanoparticle delivery can reduce side effects of the cancer drug doxorubicin.

Cyclosporine is more effective than betamethasone for treating alopecia areata, despite mild side effects.

Topical vasoconstrictors do not reduce chemotherapy effectiveness against leukemia in mice.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.

Combination therapy with cyclosporine and low-dose corticosteroid shows favorable long-term results for treating alopecia areata.

Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.

A cat had a rare severe reaction to fenbendazole, but recovered with treatment.

High-dose methotrexate can cause severe skin and nail issues.

Two transplant patients on cyclosporine unexpectedly developed hair loss.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.